Lilly’s Donanemab Slows Clinical Decline of Alzheimer’s Disease

Abington Neurological Associates is proud to have participated in the TRAILBLAZER-ALZ study that produced these results.

Donanemab met the primary endpoint of change from baseline to 76 weeks in the Integrated Alzheimer’s Disease Rating Scale (iADRS), slowing decline by 32 percent relative to placebo, which was statistically significant. The iADRS is a clinical composite tool combining the cognitive measure ADAS-Cog13 and functional measure ADCS-iADL, two commonly used measures in Alzheimer’s disease.